Le medicament du mois. Le tiotropium (SPIRIVA)

[en] SPIRIVA (tiotropium) is a long-acting anticholinergic bronchodilatator, inhaled once a day, which produces relaxation of airway smooth muscle through antagonism of acetylcholine at M3-muscarinic receptors. Its duration of action is at least 24h with once daily administration of tiotropium. Several studies have shown its efficacy and its good tolerance in the treatment of patients who are suffering from moderate to very severe chronic obstructive pulmonary disease (COPD). SPIRIVA improves spirometric measurements and quality of life, and reduces dyspnea and exacerbation rate in COPD patients.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Corhay, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

Language :

French

Title :

Le medicament du mois. Le tiotropium (SPIRIVA)

Publication date :

September 2004

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

530-3

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be/index.php?page=listeArt?date=2004%20Sep&langue=FR&limite=10

Available on ORBi :

since 17 March 2009

Statistics

Number of views

293 (0 by ULiège)

Number of downloads

258 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Lopez AD, Murray CCJL. - The global burden of disease, 1990-2020. Nat Med, 1998, 4, 1241-1243.
Lundback B, Lindberg A, Lindstrom M, et al. - Not 15 but 50% of smokers develop COPD ? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med, 2003, 97, 115-122.
Pauwels RA, Buist AS, Calverley PMA, et al. - Global strategy for the diagnosis, management, and prevention of chronic obstructive disease, NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop report (updated 2003; available at www.goldcopd.com. Accessed December 19, 2003). Am J Respir Crit Care Med, 2001, 163, 1256-1276
Disse B, Speck GA, Rominger K.L et al. - Tiotropium (Spiriva®): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci, 1999, 64, 457-464.
Disse B, Reichl R, Speck GA et al. - Ba679 Br., a novel anticholinergic bronchodilatator. Life Sci, 1993, 52, 537-544.
Maessen FP, Smeets JJ, Sledsens TJ et al. - Tiotropium bromide, a new long-acting antimuscarinic bronchodilatator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD), Dutch study group. Eur respir J, 1995, 8, 1506-1513.
Casaburi R, Mahler DA, Jones PW et al. - A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 2002, 19, 217-224.
van Noord JA, Smeets JJ, Custers FLJ et al. - Pharmacodynamic steady state of tiotropium in patients with chronic obstructive disease. Eur Respir J, 2002, 19, 639-644.
Vincken W, van Noord JA, Greefhorst APM et al. - Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J, 2002, 19, 209-216.
Donohue JF, van Noord JA, Bateman ED et al. - A 6 month, placebo-controled study comparing lung fonction and health status changes in COPD patients treated with tiotropium or salmeterol. Chest, 2002, 122, 47-55.
Brusasco V, Hodder R, Miravitlles M et al. - Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 2003, 58, 399-404.
van Noord JA, Aumann J, Janssens E et al. - Comparaison of once-daily tiotropium, twice daily formoterol and the free combination once-daily, in patients with COPD. Am J Respir Crit Med, 2003, 167 (7), A320
van Noord JA, Aumann J, Janssens E et al. - Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods. Am J Respir Crit Med, 2003, 167 (7), A95
Combivent inhalation Aerosol Study Group. - In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either alone: an 85-day multicenter trial. Chest 1994, 105, 1411-1419.
van Noord JA, de Munck DR, Bantje TA et al. - Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratriopium. Eur Respir J, 2000, 15, 878-885.
O'Donnell DE, Magnussen H, Aguilaniu B et al. - SPIRIVA® (tiotropium) improves exercise tolerance in COPD (abstract). Am J Respir Crit Care Med, 2002, 165, A227.
O'Donnell DE, Magnussen H, Aguilaniu B et al. - SPIRIVA® (tiotropium) reduces exertional dyspnea in COPD (abstract). Am J Respir Crit Care Med, 2002, 165, A265.
Chodosh S, Flanders JS, Kesten S et al. - Effective delivery of particles with HandiHaler, dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aeros Med, 2001, 14, 309-315.